MedPage Today -- The addition of an anti-tumor necrosis factor (TNF) biologic agent early in the course of Crohn’s disease may improve the likelihood of clinical remission and possibly modify the course of the disease, researchers said.
MedPage Today -- The addition of an anti-tumor necrosis factor (TNF) biologic agent early in the course of Crohn’s disease may improve the likelihood of clinical remission and possibly modify the course of the disease, researchers said.
